Solural Pharma ApS spin-out technology and together with Østjysk Innovation A/S form a new company Oncoral Pharma ApS with the purpose to develop a new tablet treatment of an existing intravenous chemotheraphy.

New agreement

September 20, 2013

Solural Pharma ApS enters into a Master Service Agreement with a major US Pharmaceutical company on the development of a new oral treatment within hormone disorders.